A PK/PD approach on the effects of clarithromycin against oral and nasal microbiota of healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 2, 2009, Pages 96-103

  Del Bortolo Ruenis, A P ^a   Nobre Franco, G C ^b   Baglie, S ^f   Lopes Motta, R H ^c   Simoes R P ^a   Rosalen, P L ^a   Franco, L M ^d   Moreno, R A ^e   Abib, Jr ^e   Groppo, F C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF TAUBATÉ   (Brazil)

^c São Leopoldo Dentistry School   (Brazil)

^d METHODIST UNIVERSITY OF PIRACICABA   (Brazil)

^e Synchrophar Assessoria e Desenvolvimento de Projetos Clinicos   (Brazil)

^f STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

Author keywords

Clarithromycin; PK PD; Staphylococci; Streptococci

Indexed keywords

CLARITHROMYCIN; CLARITROMICINA; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROFLORA; MINIMUM INHIBITORY CONCENTRATION; MOUTH FLORA; NORMAL HUMAN; NOSE; NOSE MUCOSA; OPEN STUDY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS; STREPTOCOCCUS; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; COMPARATIVE STUDY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; NOSE CAVITY; SALIVA; TIME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CLARITHROMYCIN; CROSS-OVER STUDIES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NASAL CAVITY; SALIVA; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 62749167068     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47096     Document Type: Article

References (26)

1. Alou L, Sevillano D, Bugella JH, Fuentes F, Gomez-Lus ML, Prieto J. Evaluation of two in vitro pharmacodynamic simulation models: microfiltration versus centrifugation-filtration. Int J Antimicrob Agents. 2001; 17: 365-370.
2. Amsden GW. Advanced generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents. 2001; 18 (Suppl 1): 11-15.
3. Anvisa - National Health Surveillance Agency - Brazil. Resolution - RE no 84 of March 2, 2002. Available in: http://www.anvisa.gov.br/ hotsite/genericos/legis/resolucoes/84_02rdc_e.htm> Accessed: July 14, 2008.
4. Anzueto A, Norris S. Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int J Antimicrob Agents. 2004; 24: 1-17.
5. Benet LZ. Understanding bioequivalence testing. Transplant Proc. 1999; 31 (Suppl 3A): 7S-9S.
6. Benson CA, Segreti J, Beaudette FE, Hines DW, Goodman LJ, Kaplan RL, Trenholme GM. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. Antimicrob Agents Chemother. 1987; 31: 328-330.
7. Bonapace CR, Friedrich LV, Bosso JA, White RL. Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother. 2002; 46: 3574-3579.
8. Burgess DS, Hastings RW, Horan JL. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. Ann Pharmacother. 1999; 33: 1262-1265.
9. Chin NX, Neu NM, Labthavikul P, Saha G, Neu HC. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1987; 31: 463-466.
10. Concia E, Novelli A, Schito GC, Marchese A. Ideal microbiological and pharmacological characteristics of a quality antimicrobial agent: comparing original and generic molecules. J Chemother. 2007; 19: 609-619.
11. Credito KL, Ednie LM, Jacobs MR, Appelbaum PC. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. Antimicrob Agents Chemother. 1999; 43: 2027-2031.
12. Fernandes PB, Bailer R, Swanson R, Hanson CW, McDonald E, Ramer N, Hardy D, Shipkowitz N, Bower RR, Gade E. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986; 30: 865-873.
13. Floyd-Reising S, Hindler JA, Young LS. In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents. Antimicrob Agents Chemother 1987; 31: 640-642.
14. Frimodt-Moller N. How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 2002; 19: 333-339.
15. Haraszthy VI, Reynolds HS, Sreenivasan PK, Subramanyam R, Cummins D, Zambon JJ. Media- and method-dependent variations in minimal inhibitory concentrations of antiplaque agents on oral bacteria. Lett Appl Microbiol. 2006; 43: 256-261.
16. Lerner FE, Caliendo G, Santagada V, Santana GSM, Moraes MEA, De Nucci G. Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers. Int J Clin Pharmacol Ther. 2000; 38: 345-354.
17. Morihana T, Kaneko A, Tomita F, Suwa T, Kohno Y, Kobayashi I. Penetration of clarithromycin to saliva and its effect on normal salivary bacterial flora. Jpn J Antibiot. 1989; 42: 973-982.
18. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J. 1997; 16: 438-443.
19. Noreddin AM, Roberts D, Nichol K, Wierzbowski A, Hoban DJ, Zhanel GG. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother. 2002; 46: 4029-4034.
20. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet. 1999; 37: 385-398.
21. Ruenis AP, Moreno RA, Abib-Junior E, Simoes RP, Franco LM, Groppo FC, Baglie S, Franco GC, Rosalen PL. Comparative bioavailability of clarithromycin formulations in healthy Brazilian volunteers. Int J Clin Pharmacol Ther. 2005; 43: 399-404.
22. Soriano F, Rodriguez-Cerrato V. Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract. J Antimicrob Chemother. 2002; 50 Suppl 2: 51-58.
23. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998; 27: 10-22.
24. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 2001; 18 (Suppl 1): S17-23.
25. Visalli MA, Jacobs MR, Appelbaum PC. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. Diagn Microbiol Infect Dis. 1997; 28: 131-137.
26. Wust J, Hardegger U. Penetration of clarithromycin into human saliva. Chemotherapy. 1993; 39: 293-296.